Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Review

Volume 11, Number 5, October 2022, pages 159-166

Intravenous Fluid Administration and the Risk of Adverse Outcomes in Sickle Cell Disease Patients Hospitalized for Vaso-Occlusive Crisis

Figure

Figure 1.
Figure 1. Summary of records identification, screening, eligibility, and inclusion per PRISMA guideline. PRISMA: the preferred reporting items for systematic reviews and meta-analyses. EHA: European Hematology Association; ASH: American Society of Hematology.

Table

Table 1. Characteristics of the Included Studies
 
Study/yearDesignNo. of patients/no. of VOC encountersGenotypeTypes of IVF usedAge (years)Volume of IVF per stayDuration of stay (h)Adverse outcomes of interest
aPediatric volume. bDuration of hospitalization in those who developed volume overload. cDuration of hospitalization in those without volume overload. VOC: vaso-occlusive crisis; Hb: hemoglobin; NS: normal saline; RCS: retrospective cohort study; IVF: intravenous fluid; Thal: thalassemia; SD: standard deviation; NS: normal saline; LR: lactated ringers; D5: 5% dextrose; D2.5: 2.5% dextrose; KCl: potassium chloride; ICU: intensive care unit; ED: emergency department.
Carden et al, 2019 [19]RCS400/-HbSS, HbSβ0-thalNS, LR, 1/2NS, D5NS, D5 1/2NS, D5 1/4NS, D5NS + KCl 20 mEq, D5 + 1/2NS + KCl 20 mEq13.8 (3 - 21)18.2 ± 9.5 mL/kg5.1 (SD = 2.3)Pain control
Hospital admission from ED
Gaut et al, 2020 [20]RCS49/157HbSS, HbSC-36 (SD = 7.9)7.4 L (SD = 9.6)96 (48 - 168)New oxygen requirement
Acute kidney injury
Acute chest syndrome
ICU transfer
Any adverse events
Gaartman et al, 2021 [21]RCS100/230HbSS, HbSC, HbSβ0-thal, HbSβ+-thalNS, 0.65% NS, D2.5 + 1/2NS25 (18.3 - 33.8)3 L/24 h or 3 L/m2/24 ha144 (96 - 240)b 96 (72 - 144)cVolume overload
Predictors of volume overload